Alembic Pharmaceuticals Monday said it has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder.
The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Wyeth Pharma Inc's Pristiq tablets, Alembic Pharmaceuticals said in a regulatory filing.
According to IQVIA, Desvenlafaxine extended-release tablets has a market size of around USD 13.3 million for twelve months ending December 2017.
Alembic shares were trading at 0.25 per cent up at Rs 649.30 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
